Abstract: A seat console assembly for a working machine includes a seat console support; a seat console body movably mounted to the seat console support and movable relative thereto between an operating position and a retracted position; a safety lever movably mounted to the seat console body and movable relative thereto between a blocking position and a non-blocking position for respectively blocking and unblocking an exit passage of the working machine when the seat console body is in the operating position; and a positioning mechanism configured to move the safety lever from the blocking to the non-blocking position in response to the seat console body being moved from the operating to the retracted position. The positioning mechanism is configured such that the safety lever is independently movable with respect to the seat console body from the blocking to the non-blocking position and/or from the non-blocking to the blocking position.

Abstract: The present invention provides a method of using arylpiperazine derivatives for treating pulmonary fibrosis. The method comprises a step of administering to a pulmonary fibrosis patient in need thereof an effective amount of a compound of Formula 1, which is an arylpiperazine derivative.

Abstract: The present invention provides a method of using arylpiperazine derivatives for treating pulmonary fibrosis. The method comprises a step of administering to a pulmonary fibrosis patient in need thereof an effective amount of a compound of Formula 1, which is an arylpiperazine derivative.

Abstract: The present invention provides a method of using arylpiperazine derivatives for treating pulmonary fibrosis. The method comprises a step of administering to a pulmonary fibrosis patient in need thereof an effective amount of a compound of Formula 1, which is an arylpiperazine derivative.

Abstract: The present invention provides a method of using arylpiperazine derivatives for treating pulmonary hypertension. The method comprises a step of administering to a patient in need thereof an effective amount of a compound of Formula 1, which is an arylpiperazine derivative.

Abstract: The present invention provides a method of using arylpiperazine derivatives for treating Parkinson's disease. The method is particularly effective for treating cognitive impairment associated with Parkinson's disease. The method comprises a step of administering to a patient in need thereof an effective amount of a compound of Formula I, which is an arylpiperazine derivative.

Abstract: The present invention provides novel phenylcycloalkylmethylamine derivatives, and methods of preparing phenylcycloalkylmethylamine derivatives. The present invention also provides methods of using phenylcycloalkylmethylamine derivatives and compositions of phenylcycloalkylmethylamine derivatives. The pharmaceutical compositions of the compounds of the present invention can be used for treating and/or preventing obesity and obesity related co-morbid indications and depression and depression related co-morbid indications.

Abstract: The present invention provides arylpiperazine derivatives having Formula I as shown below, which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder, and depression,

Abstract: The present invention provides novel phenylcycloalkylmethylamine derivatives, and methods of preparing phenylcycloalkylmethylamine derivatives. The present invention also provides methods of using phenylcycloalkylmethylamine derivatives and compositions of phenylcycloalkylmethylamine derivatives. The pharmaceutical compositions of the compounds of the present invention can be used for treating and/or preventing obesity and obesity related co-morbid indications and depression and depression related co-morbid indications.

Abstract: The present invention provides a method of using arylpiperazine derivatives for treating pulmonary hypertension. The method comprises a step of administering to a patient in need thereof an effective amount of a compound of Formula 1, which is an arylpiperazine derivative.

Abstract: The present invention provides a method of using arylpiperazine derivatives for treating behavioral and psychological symptoms in Alzheimer's disease patients. The method comprises a step of administering to a patient in need thereof an effective amount of a compound of Formula 1, which is an arylpiperazine derivative.

Abstract: The present invention provides a method of using arylpiperazine derivatives for treating psychosis associated with Parkinson's disease. The method comprises a step of administering to a patient in need thereof an effective amount of a compound of Formula 1, which is an arylpiperazine derivative.

Abstract: The present invention provides a method of using arylpiperazine derivatives for treating attention deficit hyperactivity disorder (ADHD). The method comprises a step of administering to a patient in need thereof an effective amount of a compound of Formula 1, which is an arylpiperazine derivative.

Abstract: The present invention provides arylpiperazine derivatives having Formula I as shown below, which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder, and depression,

Abstract: Methods and systems for determining latency in a communication network may be provided. A plurality of commands may be sent in the communication network. A response may be received for each of the plurality of commands from the communication network. A pipeline round trip time may be calculated for each of the plurality of commands based on a time of the response for each of the plurality of commands. A total round trip time for the plurality of commands may be calculated based on the calculated pipeline round trip time. A time saving may be calculated for at least one of the plurality of commands serviced locally.

Abstract: The present invention provides novel phenylcycloalkylmethylamine derivatives, and methods of preparing phenylcycloalkylmethylamine derivatives. The present invention also provides methods of using phenylcycloalkylmethylamine derivatives and compositions of phenylcycloalkylmethylamine derivatives. The pharmaceutical compositions of the compounds of the present invention can be used for treating and/or preventing obesity and obesity related co-morbid indications and depression and depression related co-morbid indications.

Abstract: The present invention provides arylpiperazine derivatives having Formula 1a as shown below, which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder, and depression,

Abstract: The present invention provides a method of using arylpiperazine derivatives for treating attention deficit hyperactivity disorder (ADHD). The method comprises a step of administering to a patient in need thereof an effective amount of a compound of Formula 1, which is an arylpiperazine derivative.

Abstract: The present invention provides arylpiperazine derivatives having Formula I as shown below, which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder, and depression,

Abstract: The present invention provides novel phenylcycloalkylmethylamine derivatives, and methods of preparing phenylcycloalkylmethylamine derivatives. The present invention also provides methods of using phenylcycloalkylmethylamine derivatives and compositions of phenylcycloalkylmethylamine derivatives. The pharmaceutical compositions of the compounds of the present invention can be used for treating and/or preventing obesity and obesity related co-morbid indications and depression and depression related co-morbid indications.